NCT06774131Phase 3Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Study sponsor: UroGen Pharma Ltd. · URGN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03Estimated

Enrollment · participants70Estimated

Source updated2026-09-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-29 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2026-10

+ Updated value

2027-03

Check registry source

Posted 2026-01-16 · 2 fields changed

Enrollment · participant count

Recorded edit

− Previous value

count: 50; type: ESTIMATED

+ Updated value

count: 70; type: ESTIMATED

Primary completion date

Recorded edit

− Previous value

2026-03-31

+ Updated value

2026-10

Check registry source